Intensity of chemotherapy for the initial management of newly diagnosed acute myeloid leukemia in older patients

Joel M. Michalski, Elizabeth R. Lyden, Andrea J. Lee, Zaid S. Al-Kadhimi, Lori J. Maness, Krishna Gundabolu, Vijaya Raj Bhatt

Research output: Contribution to journalArticle

Abstract

Aim: This study evaluated the overall survival (OS) of older patients (≥60 years) with acute myeloid leukemia based on the intensity of treatment. Methods: This single center, retrospective study included 211 patients diagnosed between 2000 and 2016, who received 10-day decitabine, low-intensity therapy or high-intensity therapy. Cox regression examined the impact of therapy on OS. Results: Younger patients were more likely to receive high-intensity therapy. Patients who received low-intensity therapy had worse OS compared with high-intensity therapy (median OS: 1.2 vs 8.5 months; p < 0.01). OS was similar with 10-day decitabine (median OS of 6.3 months) compared with either low-intensity therapy or high-intensity therapy. Conclusion: Ten-day decitabine is an effective alternative in older patients with newly diagnosed acute myeloid leukemia.

Original languageEnglish (US)
Pages (from-to)1989-1995
Number of pages7
JournalFuture Oncology
Volume15
Issue number17
DOIs
StatePublished - Jun 2019

Fingerprint

Acute Myeloid Leukemia
decitabine
Drug Therapy
Survival
Therapeutics
Retrospective Studies

Keywords

  • 10-day decitabine
  • acute myeloid leukemia
  • frail patients
  • hypomethylating agents
  • older adults
  • overall survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Intensity of chemotherapy for the initial management of newly diagnosed acute myeloid leukemia in older patients. / Michalski, Joel M.; Lyden, Elizabeth R.; Lee, Andrea J.; Al-Kadhimi, Zaid S.; Maness, Lori J.; Gundabolu, Krishna; Bhatt, Vijaya Raj.

In: Future Oncology, Vol. 15, No. 17, 06.2019, p. 1989-1995.

Research output: Contribution to journalArticle

@article{7fc07f00ec6546cbb3bfb5b2b1ed5d58,
title = "Intensity of chemotherapy for the initial management of newly diagnosed acute myeloid leukemia in older patients",
abstract = "Aim: This study evaluated the overall survival (OS) of older patients (≥60 years) with acute myeloid leukemia based on the intensity of treatment. Methods: This single center, retrospective study included 211 patients diagnosed between 2000 and 2016, who received 10-day decitabine, low-intensity therapy or high-intensity therapy. Cox regression examined the impact of therapy on OS. Results: Younger patients were more likely to receive high-intensity therapy. Patients who received low-intensity therapy had worse OS compared with high-intensity therapy (median OS: 1.2 vs 8.5 months; p < 0.01). OS was similar with 10-day decitabine (median OS of 6.3 months) compared with either low-intensity therapy or high-intensity therapy. Conclusion: Ten-day decitabine is an effective alternative in older patients with newly diagnosed acute myeloid leukemia.",
keywords = "10-day decitabine, acute myeloid leukemia, frail patients, hypomethylating agents, older adults, overall survival",
author = "Michalski, {Joel M.} and Lyden, {Elizabeth R.} and Lee, {Andrea J.} and Al-Kadhimi, {Zaid S.} and Maness, {Lori J.} and Krishna Gundabolu and Bhatt, {Vijaya Raj}",
year = "2019",
month = "6",
doi = "10.2217/fon-2019-0001",
language = "English (US)",
volume = "15",
pages = "1989--1995",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "17",

}

TY - JOUR

T1 - Intensity of chemotherapy for the initial management of newly diagnosed acute myeloid leukemia in older patients

AU - Michalski, Joel M.

AU - Lyden, Elizabeth R.

AU - Lee, Andrea J.

AU - Al-Kadhimi, Zaid S.

AU - Maness, Lori J.

AU - Gundabolu, Krishna

AU - Bhatt, Vijaya Raj

PY - 2019/6

Y1 - 2019/6

N2 - Aim: This study evaluated the overall survival (OS) of older patients (≥60 years) with acute myeloid leukemia based on the intensity of treatment. Methods: This single center, retrospective study included 211 patients diagnosed between 2000 and 2016, who received 10-day decitabine, low-intensity therapy or high-intensity therapy. Cox regression examined the impact of therapy on OS. Results: Younger patients were more likely to receive high-intensity therapy. Patients who received low-intensity therapy had worse OS compared with high-intensity therapy (median OS: 1.2 vs 8.5 months; p < 0.01). OS was similar with 10-day decitabine (median OS of 6.3 months) compared with either low-intensity therapy or high-intensity therapy. Conclusion: Ten-day decitabine is an effective alternative in older patients with newly diagnosed acute myeloid leukemia.

AB - Aim: This study evaluated the overall survival (OS) of older patients (≥60 years) with acute myeloid leukemia based on the intensity of treatment. Methods: This single center, retrospective study included 211 patients diagnosed between 2000 and 2016, who received 10-day decitabine, low-intensity therapy or high-intensity therapy. Cox regression examined the impact of therapy on OS. Results: Younger patients were more likely to receive high-intensity therapy. Patients who received low-intensity therapy had worse OS compared with high-intensity therapy (median OS: 1.2 vs 8.5 months; p < 0.01). OS was similar with 10-day decitabine (median OS of 6.3 months) compared with either low-intensity therapy or high-intensity therapy. Conclusion: Ten-day decitabine is an effective alternative in older patients with newly diagnosed acute myeloid leukemia.

KW - 10-day decitabine

KW - acute myeloid leukemia

KW - frail patients

KW - hypomethylating agents

KW - older adults

KW - overall survival

UR - http://www.scopus.com/inward/record.url?scp=85068564885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068564885&partnerID=8YFLogxK

U2 - 10.2217/fon-2019-0001

DO - 10.2217/fon-2019-0001

M3 - Article

C2 - 31170814

AN - SCOPUS:85068564885

VL - 15

SP - 1989

EP - 1995

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 17

ER -